Skip to content

Immune cell activation following ischemic cerebrovascular events: a multimodal exploratory study

Immune cell activation following ischemic cerebrovascular events: a multimodal exploratory study - Immune Activation after Stroke

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON49930
Enrollment
10
Registered
2021-08-10
Start date
Unknown
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis Cerebrovascular disease

Interventions

None listed

Sponsors

Universitair Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: - Age >18 years - Stroke or TIA with signs or ischemia on imaging compatible with the neurological deficit. - Scheduled for carotid endarterectomy based on current clinical standards

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - Severe disability (stay in nursing home). - Auto-immune or auto-inflammatory disease - Current use of immunomodulating drugs - Recent infection with fever >38.5 C

Design outcomes

Primary

MeasureTime frame
1. Markers of macrophage proliferation and activation in the explanted carotid plaque. 2. Markers of proliferation of the HSPCs and the composition and phenotype of the HSPCs in the bone marrow aspirate 3. Number and phenotype of circulating myeloid cells.

Secondary

MeasureTime frame
1. 18F-FDG uptake in the culprit carotid artery (ie the carotid artery that corresponds with the neurological symptoms of the TIA or stroke and will be operated) and the other large arteries (including aorta, carotid arteries, iliac arteries) 2. 18F-FDG uptake in the bone marrow

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)